Pulmonary mucormycosis

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 6, 2011, Pages 693-702

  Hamilos, Georgios ^a   Samonis, George ^a   Kontoyiannis, Dimitrios P ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

hematologic malignancy; immunocompromised; Mucor; Mucormycosis; Rhizopus; zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ECHINOCANDIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; POLYENE; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS; CLINICAL FEATURE; DIABETES MELLITUS; DRUG MEGADOSE; ENDOTHELIUM CELL; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; INNATE IMMUNITY; IRON METABOLISM; LUNG ASPERGILLOSIS; LUNG INFECTION; MUCORALES; MUCORMYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK FACTOR; SURGICAL APPROACH; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; DEBRIDEMENT; HUMANS; HYPERBARIC OXYGENATION; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; MUCOR; MUCORALES; MUCORMYCOSIS; OPPORTUNISTIC INFECTIONS; RHIZOMUCOR; RHIZOPUS;

EID: 83655193163     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1295717     Document Type: Article

References (64)

1. Ribes J A., Vanover-Sams C L., Baker D J. Zygomycetes in human disease. Clin Microbiol Rev 2000 13 2 236-301 (Pubitemid 30205427)
2. Roden M M., Zaoutis T E., Buchanan W L. et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005 41 5 634-653 (Pubitemid 41170352)
3. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005 18 3 556-569 (Pubitemid 40995116)
4. Kontoyiannis D P., Lewis R E. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006 20 3 581-607 vi (Pubitemid 44375113)
5. Hibbett D S., Binder M, Bischoff J F. et al. A higher-level phylogenetic classification of the fungi. Mycol Res 2007 111 Pt 5 509-547 (Pubitemid 46915419)
6. Gomes M Z., Lewis R E., Kontoyiannis D P. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev 2011 24 2 411-445
7. Park B J., Pappas P G., Wannemuehler K A. et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011 17 10 1855-1864
8. Kontoyiannis D P., Lionakis M S., Lewis R E. et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005 191 8 1350-1360
9. Imhof A, Balajee S A., Fredricks D N., Englund J A., Marr K A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004 39 5 743-746 (Pubitemid 39180450)
10. Siwek G T., Dodgson K J., de Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004 39 4 584-587 (Pubitemid 39120940)
11. Marty F M., Cosimi L A., Baden L R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004 350 9 950-952 (Pubitemid 38252550)
12. Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007 40 5 451-456 (Pubitemid 47288224)
13. Chamilos G, Luna M, Lewis R E. et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006 91 7 986-989 (Pubitemid 44023159)
14. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 19972006. Emerg Infect Dis 2009 15 9 1395-1401
15. Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis 2010 16 9 1456-1458
16. Lamaris G A., Ben-Ami R, Lewis R E., Chamilos G, Samonis G, Kontoyiannis D P. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009 199 9 1399-1406
17. Singh N, Aguado J M., Bonatti H et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009 200 6 1002-1011
18. Kontoyiannis D P., Wessel V C., Bodey G P., Rolston K V. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000 30 6 851-856 (Pubitemid 32250321)
19. Wingard J R., Carter S L., Walsh T J. et al, Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010 116 24 5111-5118
20. Pongas G N., Lewis R E., Samonis G, Kontoyiannis D P. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009 15 Suppl 5 93-97
21. Chamilos G, Ganguly D, Lande R et al. Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. PLoS One 2010 5 9 e12955
22. Chamilos G, Lewis R E., Lamaris G, Walsh T J., Kontoyiannis D P. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008 52 2 722-724 (Pubitemid 351170850)
23. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn R M., Walsh T J. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005 191 7 1180-1187 (Pubitemid 40404378)
24. Chamilos G, Lewis R E., Hu J et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008 105 27 9367-9372
25. Boelaert J R., de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993 91 5 1979-1986 (Pubitemid 23141469)
26. Ibrahim A S., Gebermariam T, Fu Y et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007 117 9 2649-2657 (Pubitemid 47494365)
27. Ibrahim A S., Gebremariam T, Lin L et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010 77 3 587-604
28. Artis W M., Patrusky E, Rastinejad F, Duncan R L. Jr. Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation. Infect Immun 1983 41 3 1269-1278 (Pubitemid 13048606)
29. Artis W M., Fountain J A., Delcher H K., Jones H E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982 31 12 1109-1114 (Pubitemid 13242245)
30. Reed C, Ibrahim A, Edwards J E. Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006 50 11 3968-3969 (Pubitemid 44684931)
31. Ibrahim A S., Spellberg B, Avanessian V, Fu Y, Edwards J E. Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005 73 2 778-783 (Pubitemid 40165733)
32. Liu M, Spellberg B, Phan Q T. et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010 120 6 1914-1924
33. Lee F Y., Mossad S B., Adal K A. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999 159 12 1301-1309 (Pubitemid 29293592)
34. Chamilos G, Marom E M., Lewis R E., Lionakis M S., Kontoyiannis D P. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005 41 1 60-66 (Pubitemid 40863745)
35. McAdams H P., Rosado de Christenson M, Strollo D C., Patz E F. Jr. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997 168 6 1541-1548
36. Wahba H, Truong M T., Lei X, Kontoyiannis D P., Marom E M. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008 46 11 1733-1737 (Pubitemid 351706772)
37. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D, Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Transplantation 2000 70 1 112-116 (Pubitemid 30490761)
38. Hosseini-Moghaddam S M., Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010 31 2 222-233
39. Glazer M, Nusair S, Breuer R, Lafair J, Sherman Y, Berkman N. The role of BAL in the diagnosis of pulmonary mucormycosis. Chest 2000 117 1 279-282 (Pubitemid 30053653)
40. Frater J L., Hall G S., Procop G W. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001 125 3 375-378 (Pubitemid 32207175)
41. Kontoyiannis D P., Chamilos G, Hassan S A., Lewis R E., Albert N D., Tarrand J J. Increased culture recovery of Zygomycetes under physiologic temperature conditions. Am J Clin Pathol 2007 127 2 208-212 (Pubitemid 46797177)
42. Rickerts V, Mousset S, Lambrecht E et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007 44 8 1078-1083 (Pubitemid 46580276)
43. Bialek R, Konrad F, Kern J et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 2005 58 11 1180-1184 (Pubitemid 41566463)
44. Lass-Flörl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007 45 7 e101-e104 (Pubitemid 47580399)
45. Tedder M, Spratt J A., Anstadt M P., Hegde S S., Tedder S D., Lowe J E. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994 57 4 1044-1050 (Pubitemid 24133513)
46. Chamilos G, Lewis R E., Kontoyiannis D P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008 47 4 503-509
47. Perfect J R. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005 40 Suppl 6 S401-S408 (Pubitemid 40563297)
48. Walsh T J., Hiemenz J W., Seibel N L. et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 26 6 1383-1396 (Pubitemid 28270170)
49. Walsh T J., Goodman J L., Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001 45 12 3487-3496 (Pubitemid 33107867)
50. Revankar S G., Hasan M S., Smith J W. Cure of disseminated zygomycosis with cerebral involvement using high dose liposomal amphotericin B and surgery. Med Mycol 2007 45 2 183-185 (Pubitemid 46371961)
51. Cornely O A., Maertens J, Bresnik M et al, AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 44 10 1289-1297 (Pubitemid 46717290)
52. Lewis R E., Albert N D., Liao G, Hou J, Prince R A., Kontoyiannis D P. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010 54 3 1298-1304
53. Safdar A, OBrien S, Kouri I F. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 2004 34 5 467-468 (Pubitemid 39232379)
54. Dannaoui E, Meis J F., Loebenberg D, Verweij P E. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003 47 11 3647-3650 (Pubitemid 37345740)
55. Dannaoui E, Meletiadis J, Mouton J W., Meis J F., Verweij P E., Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003 51 1 45-52 (Pubitemid 36163826)
56. Greenberg R N., Mullane K, van Burik J A. et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006 50 1 126-133 (Pubitemid 43042912)
57. van Burik J A., Hare R S., Solomon H F., Corrado M L., Kontoyiannis D P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006 42 7 e61-e65
58. Lekakis L J., Lawson A, Prante J et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant 2009 15 8 991-995
59. Ibrahim A S., Bowman J C., Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005 49 2 721-727 (Pubitemid 40175685)
60. Ibrahim A S., Gebremariam T, Fu Y, Edwards J E. Jr, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008 52 4 1556-1558 (Pubitemid 351522035)
61. Reed C, Bryant R, Ibrahim A S. et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008 47 3 364-371 (Pubitemid 352009357)
62. John B V., Chamilos G, Kontoyiannis D P. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005 11 7 515-517 (Pubitemid 40895150)
63. Grigull L, Beilken A, Schmid H et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer 2006 14 7 783-786 (Pubitemid 43886921)
64. Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009;5(7):e1000549